Akèy › Sipwa
Etid klinik pou Sipwa ap rekrite nan Etazini
203 etid pou Sipwa ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX33 etid
- San Antonio, TX33 etid
- Chicago, IL28 etid
- Orlando, FL25 etid
- Miami, FL23 etid
- Las Vegas, NV23 etid
- Dallas, TX20 etid
- Atlanta, GA20 etid
- New York City, NY19 etid
- Jacksonville, FL19 etid
- Washington, DC19 etid
- Austin, TX18 etid
- Havelock, NC17 etid
- Baltimore, MD17 etid
- Birmingham, AL16 etid
- Concord, CA16 etid
- Charlotte, NC15 etid
- Louisville, KY15 etid
- Tucson, AZ15 etid
- Phoenix, AZ15 etid
- St. Louis, MO15 etid
- Los Angeles, CA14 etid
- Johns Creek, GA14 etid
- Cincinnati, OH14 etid
- Philadelphia, PA14 etid
- Indianapolis, IN13 etid
- Rochester, NY13 etid
- San Diego, CA13 etid
- Columbus, OH13 etid
- Salt Lake City, UT13 etid
- Escondido, CA12 etid
- Greensboro, NC12 etid
- Boston, MA12 etid
- Wilmington, NC11 etid
- Arlington, VA11 etid
- Honolulu, HI11 etid
- Grand Prairie, TX11 etid
- South Fulton, GA11 etid
- Pittsburgh, PA10 etid
- O'Fallon, MO10 etid
Pa eta
- Alabama31 etid
- Arizona29 etid
- Arkansas6 etid
- Ayiti11 etid
- Colorado11 etid
- Connecticut16 etid
- Distrik Columbia7 etid
- Florid53 etid
- Georgia36 etid
- Idaho19 etid
- Illinois38 etid
- Indiana16 etid
- Iowa9 etid
- Kalifòni63 etid
- Kansas26 etid
- Kentucky21 etid
- Lwizyàn23 etid
- Maryland37 etid
- Massachusetts24 etid
- Michigan19 etid
- Minnesota13 etid
- Mississippi11 etid
- Missouri33 etid
- Montana6 etid
- Nebraska7 etid
- Nevada24 etid
- New Hampshire3 etid
- New Jersey16 etid
- New Mexico4 etid
- New York45 etid
- North Carolina40 etid
- North Dakota8 etid
- Ohio35 etid
- Oklahoma18 etid
- Oregon13 etid
- Pennsylvania32 etid
- Rhode Island13 etid
- South Carolina35 etid
- South Dakota4 etid
- Tennessee25 etid
- Texas54 etid
- Utah22 etid
- Virginia33 etid
- Washington23 etid
- Wisconsin8 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Two-Week Stair-Climbing Exercise Snacks and Metabolic Health in Adults With Overweight or Obesity: A Pilot Study
Ap rekriteVolontè an sante akeyi
Laj 18 a 35 · Tout sèks · Mizajou Sep 30, 2026 · NCT07849439A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Ap rekriteFaz 3
Laj 8 a 18 · Tout sèks · Mizajou Sep 30, 2026 · NCT07253285AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07533175Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07685808A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07823608Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07752979FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT06724406AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07720271A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07595549Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 60 · Fanm · Mizajou Sep 28, 2026 · NCT03407079Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07837973A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07668414A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Sep 28, 2026 · NCT07399678Physical and Behavioral Traits of Overweight and Obese Adults
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT00428987Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07594093A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07776509A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 23, 2026 · NCT07803744A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.